MCL1 and acute myeloid leukemia: As one could expect, this property of LY2603618 rendered its ability to overcome intrinsic resistance to the Bcl-2-selective inhibitor ABT-199, mediated by Mcl-1 in AML cells, leading to synergistic antileukemic interactions between the two agents in both AML cell lines and primary AML patient samples.